Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis.

McTigue MA, Wickersham JA, Pinko C, Showalter RE, Parast CV, Tempczyk-Russell A, Gehring MR, Mroczkowski B, Kan CC, Villafranca JE, Appelt K.

Structure. 1999 Mar 15;7(3):319-30.

2.

Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis.

Parast CV, Mroczkowski B, Pinko C, Misialek S, Khambatta G, Appelt K.

Biochemistry. 1998 Nov 24;37(47):16788-801.

PMID:
9843450
3.

Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.

Shibuya M, Seetharam L, Ishii Y, Sawano A, Gotoh N, Matsushime H, Yamaguchi S.

Princess Takamatsu Symp. 1994;24:162-70. Review.

PMID:
8983073
4.

Structure of the Tie2 RTK domain: self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail.

Shewchuk LM, Hassell AM, Ellis B, Holmes WD, Davis R, Horne EL, Kadwell SH, McKee DD, Moore JT.

Structure. 2000 Nov 15;8(11):1105-13.

5.

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.

Lee CC, Jia Y, Li N, Sun X, Ng K, Ambing E, Gao MY, Hua S, Chen C, Kim S, Michellys PY, Lesley SA, Harris JL, Spraggon G.

Biochem J. 2010 Sep 15;430(3):425-37. doi: 10.1042/BJ20100609.

PMID:
20632993
6.

HCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity.

Huang L, Sankar S, Lin C, Kontos CD, Schroff AD, Cha EH, Feng SM, Li SF, Yu Z, Van Etten RL, Blanar MA, Peters KG.

J Biol Chem. 1999 Dec 31;274(53):38183-8.

7.
8.

Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor.

Pan B, Li B, Russell SJ, Tom JY, Cochran AG, Fairbrother WJ.

J Mol Biol. 2002 Feb 22;316(3):769-87.

PMID:
11866530
10.

Characterization of the VEGF binding site on the Flt-1 receptor.

Herley MT, Yu Y, Whitney RG, Sato JD.

Biochem Biophys Res Commun. 1999 Sep 7;262(3):731-8.

PMID:
10471394
11.
12.

Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues.

Kendall RL, Rutledge RZ, Mao X, Tebben AJ, Hungate RW, Thomas KA.

J Biol Chem. 1999 Mar 5;274(10):6453-60.

14.

Crystal structure of the complex between VEGF and a receptor-blocking peptide.

Wiesmann C, Christinger HW, Cochran AG, Cunningham BC, Fairbrother WJ, Keenan CJ, Meng G, de Vos AM.

Biochemistry. 1998 Dec 22;37(51):17765-72.

PMID:
9922142
15.

Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF.

Piossek C, Schneider-Mergener J, Schirner M, Vakalopoulou E, Germeroth L, Thierauch KH.

J Biol Chem. 1999 Feb 26;274(9):5612-9.

16.

Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism.

Mohammadi M, Schlessinger J, Hubbard SR.

Cell. 1996 Aug 23;86(4):577-87.

17.

The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells.

Warner AJ, Lopez-Dee J, Knight EL, Feramisco JR, Prigent SA.

Biochem J. 2000 Apr 15;347(Pt 2):501-9.

19.

Crystallization of the receptor binding domain of vascular endothelial growth factor.

Christinger HW, Muller YA, Berleau LT, Keyt BA, Cunningham BC, Ferrara N, de Vos AM.

Proteins. 1996 Nov;26(3):353-7.

PMID:
8953654
20.

VEGFR and type-V RTK activation and signaling.

Shibuya M.

Cold Spring Harb Perspect Biol. 2013 Oct 1;5(10):a009092. doi: 10.1101/cshperspect.a009092. Review.

Supplemental Content

Support Center